Tests olpasiran for heart events in people with high lipoprotein(a)
Tests olpasiran against placebo in adults with high lipoprotein(a) at risk of heart events.
Plain-language title generated from the registry record
Registry title: OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Key facts
- Where
- Auchenflower, Bedford Park, Camperdown, Charlestown, Clayton, Concord, Garran, Greenfields, Joondalup, Leabrook, Melbourne, Merewether, Milton, Nedlands, Norwood, Orange, Perth, Sippy Downs, Wollongong, and Woolloongabba, AustraliaSee the 22 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 105 years old?
Source: NCT07136012, who can take part
Where in Australia
- Advara HeartCare WesleyAuchenflower, AustraliaTaking people
- Flinders Medical CentreBedford Park, AustraliaTaking people
- Royal Prince Alfred HospitalCamperdown, AustraliaTaking people
- NovatrialsCharlestown, AustraliaTaking people
- Victorian Heart HospitalClayton, AustraliaTaking people
- Concord Repatriation General HospitalConcord, AustraliaTaking people
- Canberra HospitalGarran, AustraliaTaking people
- Clinitrials - MandurahGreenfields, AustraliaTaking people
- Advara HeartCare JoondalupJoondalup, AustraliaTaking people
- Advara HeartCare LeabrookLeabrook, AustraliaTaking people
- Momentum Clinical Research - SunshineMelbourne, AustraliaTaking people
- The Alfred HospitalMelbourne, AustraliaTaking people
- Aim ResearchMerewether, AustraliaTaking people
- Core Research Group Pty LtdMilton, AustraliaTaking people
- Hollywood Private HospitalNedlands, AustraliaTaking people
- Linear Clinical Research LimitedNedlands, AustraliaTaking people
- Fusion Clinical ResearchNorwood, AustraliaTaking people
- Orange Health ServiceOrange, AustraliaTaking people
- Clinitrials - West PerthPerth, AustraliaTaking people
- University of The Sunshine Coast Clinical Trials, Sippy DownsSippy Downs, AustraliaTaking people
- Wollongong HospitalWollongong, AustraliaTaking people
- Dr Heart Pty LtdWoolloongabba, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amgen
- Trial code
- NCT07136012
- Record updated
- 21 August 2026
- Original description
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp[a]).Read full original descriptionShow less
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp[a]).
Inclusion: Age ≥50 years; Lp(a)≥ 200 nmol/L during screening; Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis.
Exclusion: Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia); Prior or planned arterial revascularization; History of major bleeding disorder.